{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:53:46Z","timestamp":1793890426739,"version":"4.8.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"AVIR Green Hills Biotechnology Research Development AG, Austria"},{"DOI":"10.13039\/501100009706","name":"EU","doi-asserted-by":"publisher","award":["518281"],"award-info":[{"award-number":["518281"]}],"id":[{"id":"10.13039\/501100009706","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.vaccine.2019.05.013","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T01:41:13Z","timestamp":1559180473000},"page":"3722-3729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1"],"prefix":"10.1016","volume":"37","author":[{"given":"Christina","family":"Nicolodi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Groiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Kiselev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wolschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Seipelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Muster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.05.013_b0010","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.05.013_b0025","doi-asserted-by":"crossref","DOI":"10.1126\/science.279.5349.393","article-title":"Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness","author":"Subbarao","year":"1998","journal-title":"Science (80-)"},{"key":"10.1016\/j.vaccine.2019.05.013_b0030","article-title":"Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness","author":"WHO","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2019.05.013_b0035","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa044021","article-title":"Probable person-to-person transmission of avian Influenza A (H5N1)","author":"Ungchusak","year":"2005","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.vaccine.2019.05.013_b0040","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa060930","article-title":"Three Indonesian Clusters of H5N1 Virus Infection in 2005","volume":"355","author":"Kandun","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.05.013_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(08)60493-6","article-title":"Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China","author":"Wang","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.05.013_b0050","series-title":"Cumulative number of confirmed human cases for avian influenza A (H5N1) reported to WHO, 2003\u20132017","author":"WHO","year":"2017"},{"key":"10.1016\/j.vaccine.2019.05.013_b0055","unstructured":"Organizaci\u00f3n Mundial de la Salud. Global pandemic influenza action plan to increase vaccine supply. Who\/Ivb\/0613 Who\/Cds\/Epr\/Gip\/20061; 2006."},{"key":"10.1016\/j.vaccine.2019.05.013_b0060","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.23.1.66-72.1986","article-title":"Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine","author":"Clements","year":"1986","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2019.05.013_b0065","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0264-410X(99)00183-8","article-title":"Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children","volume":"18","author":"Boyce","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.013_b0070","doi-asserted-by":"crossref","first-page":"6794","DOI":"10.1016\/j.vaccine.2012.09.018","article-title":"The role of nasal IgA in children vaccinated with live attenuated influenza vaccine","volume":"30","author":"Ambrose","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.013_b0075","doi-asserted-by":"crossref","DOI":"10.1006\/viro.1998.9508","article-title":"Influenza A virus lacking the NS1 gene replicates in interferon- deficient systems","author":"Garc\u00eda-Sastre","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.05.013_b0080","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.100133697","article-title":"A DNA transfection system for generation of influenza A virus from eight plasmids","author":"Hoffmann","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.vaccine.2019.05.013_b0085","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1128\/jvi.70.6.4188-4192.1996","article-title":"A plasmid-based reverse genetics system for influenza A virus","volume":"70","author":"Pleschka","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.05.013_b0090","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1016\/j.vaccine.2004.08.054","article-title":"Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system","volume":"23","author":"Nicolson","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.013_b0095","doi-asserted-by":"crossref","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","author":"Reed","year":"1938","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.vaccine.2019.05.013_b0100","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1128\/JVI.72.8.6437-6441.1998","article-title":"Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells","volume":"72","author":"Egorov","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.05.013_b0105","unstructured":"WHO. WHO manual on animal influenza diagnosis and surveillance. WHO Anim Influ Man; 2002."},{"key":"10.1016\/j.vaccine.2019.05.013_b0110","doi-asserted-by":"crossref","DOI":"10.3855\/jidc.3329","article-title":"Recognizing true H5N1 infections in humans during confirmed outbreaks","author":"Zaman","year":"2014","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.vaccine.2019.05.013_b0115","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00517-07","article-title":"Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects","author":"Block","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2019.05.013_b0120","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa061850","article-title":"Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines","author":"Ohmit","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2019.05.013_b0125","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJMoa065368","article-title":"Live attenuated versus inactivated influenza vaccine in infants and young children","volume":"356","author":"Belshe","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.05.013_b0130","article-title":"Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents","author":"Bergen","year":"2004","journal-title":"Pediatr Res"},{"key":"10.1016\/j.vaccine.2019.05.013_b0135","doi-asserted-by":"crossref","DOI":"10.1086\/649428","article-title":"A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1","author":"Wacheck","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.05.013_b0140","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.1016\/j.vaccine.2013.10.061","article-title":"Phase I\/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1","volume":"31","author":"M\u00f6ssler","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.013_b0145","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00534-09","article-title":"Reassortment between Avian H5N1 and human H3N2 influenza viruses in ferrets: a public health risk assessment","author":"Jackson","year":"2009","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.05.013_b0150","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1128\/jcm.32.3.750-754.1994","article-title":"Effect of simultaneous administration of cold-adapted and wild-type influenza A viruses on experimental wild-type influenza infection in humans","volume":"32","author":"Youngner","year":"1994","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2019.05.013_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2007.05.004","article-title":"Phenotypic properties resulting from directed gene segment reassortment between wild-type A\/Sydney\/5\/97 influenza virus and the live attenuated vaccine strain","author":"Parks","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.05.013_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(75)90720-5","article-title":"Trials in man with live recombinants made from A\/PR\/8\/34 (H0 N1) and wild H3 N2 influenza viruses","author":"Beare","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.05.013_b0165","first-page":"105","article-title":"Clinical acceptability of live influenza vaccine in high risk subjects and children. Experience with three consecutive recombinant strains","volume":"39","author":"Jovanovic","year":"1977","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2019.05.013_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/S0092-1157(79)80010-4","article-title":"Genotypic characterization and clinical evaluation of an influenza A\/Texas\/1\/77 (H3N2)-like recombinant: RIT 4199","author":"Florent","year":"1979","journal-title":"J Biol Stand"},{"key":"10.1016\/j.vaccine.2019.05.013_b0175","doi-asserted-by":"crossref","DOI":"10.1086\/526537","article-title":"Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans","author":"Zangwill","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.05.013_b0180","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.vaccine.2009.05.099","article-title":"Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults","volume":"27","author":"Karron","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.013_b0185","doi-asserted-by":"crossref","DOI":"10.1111\/j.1750-2659.2008.00064.x","article-title":"Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials)","author":"Rudenko","year":"2008","journal-title":"Influenza Other Respi Viru"},{"key":"10.1016\/j.vaccine.2019.05.013_b0190","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1016\/j.vaccine.2015.08.019","article-title":"Clinical testing of pre-pandemic live attenuated A\/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study","volume":"33","author":"Rudenko","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.013_b0195","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-017-0017-5","article-title":"H5N1 influenza vaccine induces a less robust neutralizing antibody response than seasonal trivalent and H7N9 influenza vaccines","author":"Wong","year":"2017","journal-title":"npj Vacc"},{"key":"10.1016\/j.vaccine.2019.05.013_b0200","doi-asserted-by":"crossref","DOI":"10.1038\/nature01783","article-title":"Viral infection switches non-plasmacytoid dendritic cells into high interferon producers","author":"Diebold","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2019.05.013_b0205","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1016\/j.vaccine.2011.02.100","article-title":"Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1","volume":"29","author":"Nakowitsch","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.013_b0210","article-title":"Impact of erythrocyte species on assays for influenza serology","author":"Trombetta","year":"2018","journal-title":"J Prev Med Hyg"},{"key":"10.1016\/j.vaccine.2019.05.013_b0215","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00921-07","article-title":"Erythrocyte binding preference of avian influenza H5N1 viruses","author":"Louisirirotchanakul","year":"2007","journal-title":"J Clin Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19306279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19306279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:32:27Z","timestamp":1759401147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19306279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":40,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0264410X19306279"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.013","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}